Insider Buying: Hims & Hers Health (NYSE:HIMS) Director Purchases 48,400 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director David Wells bought 48,400 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average cost of $24.23 per share, for a total transaction of $1,172,732.00. Following the transaction, the director directly owned 224,417 shares of the company’s stock, valued at $5,437,623.91. The trade was a 27.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $0.04 on Tuesday, hitting $23.79. The stock had a trading volume of 15,724,693 shares, compared to its average volume of 32,291,996. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The business’s 50 day moving average is $24.03 and its two-hundred day moving average is $27.85. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock has a market cap of $5.42 billion, a price-to-earnings ratio of -264.33, a price-to-earnings-growth ratio of 46.09 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the business posted $0.20 earnings per share. Hims & Hers Health’s revenue was up 3.8% compared to the same quarter last year. Analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $28,000. Silicon Valley Capital Partners acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $48,000. Flagship Harbor Advisors LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Bogart Wealth LLC increased its stake in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after buying an additional 283 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on HIMS shares. Truist Financial raised their price target on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday. Morgan Stanley lowered their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. JPMorgan Chase & Co. dropped their price objective on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Canaccord Genuity Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday, May 12th. Finally, Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $28.70.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.